4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit?

Seventeen in '17. It might sound like a slogan, but it's actually a reference to the size of the global HIV drug market. In 2017, the HIV market topped $17 billion, according to data from market research firm IMARC Group. 

The best-selling HIV drugs last year were Genvoya, Triumeq, Truvada, Tivicay, and Atripla. Gilead Sciences (NASDAQ:GILD) claimed three of these drugs, including No. 1 Genvoya. The other two top HIV drugs -- Triumeq and Tivicay -- belonged to GlaxoSmithKline (NYSE:GSK).